Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: Which best predicts virological and resistance outcomes?

AIDS Research and Therapy

Volumn 14, Issue 1, 2017, Pages

  Orrell, Catherine ^a,d   Cohen, Karen ^a   Leisegang, Rory ^a   Bangsberg, David R ^b,c   Wood, Robin ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Institute of Infectious Disease and Molecular Medicine   (South Africa)

Author keywords

Adherence; Antiretroviral therapy; Electronic monitoring; Genotyping; HIV; HIV 1 resistance; Virological outcome

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ANALYTICAL EQUIPMENT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; AVERAGE ADHERENCE BY PHARMACY REFILL; CALCULATION OF MEDICATION FREE DAY; CD4 LYMPHOCYTE COUNT; CLINIC BASED PILL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TREATMENT FAILURE; ELECTRONIC ADHERENCE MONITORING DEVICE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PHARMACOLOGICAL PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESOURCE POOR SETTING; SELF REPORT; SOCIOECONOMICS; SOUTH AFRICA; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; RNA, VIRAL; SOUTH AFRICA; SURVEYS AND QUESTIONNAIRES; TREATMENT FAILURE; VIRAL LOAD;

EID: 85016979051     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-017-0138-y     Document Type: Article

References (42)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
2. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-3.
3. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-33.
4. Glass T, Cavassini M. Asking about adherence-from flipping the coin to strong evidence. Swiss Med Wkly. 2014;144:w14016.
5. Marcellin F, Spire B, Carrieri MP, Roux P. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Rev Anti Infect Ther. 2013;11(3):239-50.
6. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19(12):1243-9.
7. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284-97.
8. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5(5):e109.
9. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84.
10. Court R, Leisegang R, Stewart A, Sunpath H, Murphy R, Winternheimer P, et al. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. BMC Infect Dis. 2014;14(1):664.
11. Marcellin F, Spire B, Carrieri MP, Roux P. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Rev Anti-Infect Ther. 2013;11(3):239-50.
12. Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, et al. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2166-8.
13. Liu X, Ma Q, Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf. 2010;9(5):743-58.
14. Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev. 2009. (3):CD007268. doi: 10.1002/14651858.CD007268.pub2.
15. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
16. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36(5):1100-2.
17. Muller AD, Jaspan HB, Myer L, Hunter AL, Harling G, Bekker LG, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011;15(2):422-31.
18. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66.
19. Ncaca LN, Kranzer K, Orrell C. Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa. PLoS ONE. 2011;6(8):e23088.
20. Orrell C, Mauff K, Bangsberg D, Maartens G, Wood R. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(5):495-502.
21. Orrell C, Kaplan R, Wood R, Bekker LG. Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. AIDS Res Treat. 2011;2011:469127.
22. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12(1):83-8.
23. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340-6.
24. Sabin LL, Bachman DeSilva M, Gill CJ, Zhong L, Vian T, Wubin X, et al. Improving adherence to antiretroviral therapy with triggered real time text message reminders: the China through technology study (CATS). J Acquir Immune Defic Syndr. 2015;69(5):551-9.
25. National Insititute on Alcohol Abuse and Alcoholism. CAGE questionnaire. http://pubs.niaaa.nih.gov/publications/inscage.htm. 2002.
26. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res. 1997;42(1):17-41.
27. Nglazi MD, Kaplan R, Wood R, Bekker LG, Lawn SD. Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. BMC Infect Dis. 2010;10:329.
28. Orrell C, Dipenaar R, Killa N, Tassie JM, Harries AD, Wood R. Simplifying HIV cohort monitoring-pharmacy stock records minimize resources necessary to determine retention in care. J Acquir Immune Defic Syndr. 2013;62(3):e106-8.
29. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-63.
30. Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383(9927):1474-82.
31. van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol. 2008;80(6):942-6.
32. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22(3):642-50.
33. Wu P, Johnson BA, Nachega JB, Wu B, Ordonez CE, Hare AQ, et al. The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa. Curr HIV Res. 2014;12(5):366-75.
34. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838-45.
35. Hardy H, Kumar V, Doros G, Farmer E, Drainoni ML, Rybin D, Myung D, Jackson J, Backman E, Stanic A, Skolnik PR. Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. AIDS Patient Care STDS. 2011;25(3):153-61. doi: 10.1089/apc.2010.0006.
36. Da Costa TM, Barbosa BJP, E Costa DAG, Sigulem D, De Fátima Marin H, Filho AC, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81(4):257-69.
37. Maduka O, Tobin-West CI. Adherence counseling and reminder text messages improve uptake of antiretroviral therapy in a tertiary hospital in Nigeria. Niger J Clin Pract. 2013;16(3):302-8. doi: 10.4103/1119-3077.113451.
38. Petersen ML, LeDell E, Schwab J, Sarovar V, Gross R, Reynolds N, et al. Super learner analysis of electronic adherence data improves viral prediction and may provide strategies for selective HIV RNA monitoring. J Acquir Immune Defic Syndr. 2015;69(1):109-18.
39. Haberer JE, Musinguzi N, Boum Y 2nd, Siedner MJ, Mocello AR, Hunt PW, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in rural Uganda. J Acquir Immune Defic Syndr. 2015;70(4):386-92.
40. Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, et al. Cost effectiveness of potential ART adherence monitoring interventions in Sub-Saharan Africa. PLoS ONE. 2016;11(12):e0167654.
41. Nglazi MD, Kaplan R, Orrell C, Myer L, Wood R, Bekker LG, et al. Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression. PLoS ONE. 2013;8(3):e57907.
42. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, Wood R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56(1):e1-8.